Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BZF961 · 1 trial · 1 indication
Viral load samples will be taken at Day 3.
| Arm | Type | Description |
|---|---|---|
| BZF961 | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| BZF961 | DRUG | There will be 2 parts to the study: Part 1: BZF monotherapy. Part 2: Cohort IIa: BZF961 monotherapy at 3 TBD doses; Cohort IIb: BZF961 in combination with ritonavir at TBD doses. |
| Ritonavir | DRUG | Ritonavir will be given as a boosting agent in Part 2, Cohort IIb in combination with BZF961 |
| Placebo | DRUG | Placebo |
Inclusion Criteria: * Written informed consent must be obtained before any assessment is performed Male \& female treatment naive subjects, age 18-60 years of age with Hepatitis C genotype-1. Subjects must weight at least 50kg to participate in the study, and must have a body mass index (BMI) withi...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Atea Pharmaceuticals, Inc. | AVIR | 2 | PHASE3 | Bemnifosbuvir-Ruzasvir, Sofosbuvir-Velpatasvir |
| Abbott Laboratories | ABT | 2 | - | Undisclosed |
| AbbVie, Inc. | ABBV | 1 | - | Undisclosed |
BZF961 is an investigational small molecule being developed for the treatment of Hepatitis C, a viral infection of the liver. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
BZF961 is a small molecule designed to target Hepatitis C. Its specific molecular target has not been disclosed in available information, but it is being studied for its antiviral effect in patients infected with the Hepatitis C virus.
BZF961 is being developed by Novartis AG, a multinational pharmaceutical company listed on the stock exchange under the ticker symbol NVS. The company is conducting clinical trials to evaluate the safety and efficacy of this investigational drug.
BZF961 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved for commercial use. The Phase 1 trial has been completed, and the drug is still in the early stages of clinical testing.
BZF961 has one completed clinical trial registered under NCT01825980, titled 'Proof of Concept Study to Determine the Safety and Antiviral Effect of BZF961 With or Without Ritonavir Boosting in Hepatitis C Virus Infected Patients.' This Phase 1 study enrolled 54 participants in the United States.
BZF961 is not known to have any alternative names. It is a unique investigational compound being developed by Novartis AG for the treatment of Hepatitis C.